Recent studies have also demonstrated that a substantial proportion of pancreatic and prostate cancer patients harbor mutations in key HRR genes, notably BRCA1/2, ATM, PALB2, and CDK12 [18–20]. The gene discussed is PALB2; the disease is prostate cancer.